Anthropic Files for IPO After Surpassing OpenAI's $965B Valuation
Anthropic confidentially filed for an IPO on June 2, 2026, days after closing a $65B Series H round that pushed its valuation to $965B, overtaking OpenAI's $852B.
Anthropic confidentially filed for an IPO on June 2, 2026, days after closing a $65B Series H round that pushed its valuation to $965B, overtaking OpenAI's $852B.
SpaceX's amended IPO prospectus now flags water availability as a critical constraint for its data center expansion, joining power as a core infrastructure bottleneck.
Anthropic submits S-1 filing for what could be the largest IPO ever, following a $65 billion funding round and annualized revenue of $47 billion.
Anthropic secures $65B in funding at a $965B post-money valuation, with lead investors including Altimeter Capital and Sequoia, ahead of expected public listing.
SpaceX's S-1 filing projects a Mars-linked valuation that would be the largest US IPO ever, but hosts question whether the addressable-market math reflects near-term reality.
SpaceX's IPO filing reveals ambitious valuation and compensation structure tied to Mars colonization, raising questions about execution and market assumptions.
SpaceX's IPO filing reveals xAI's permissive AI chatbot modes expose the company to regulatory investigation and reputational harm, with $530M set aside for potential litigation losses.
SpaceX's IPO filing reveals xAI burned $6.4 billion against $3.2 billion in revenue during 2025, with capex doubling to a $30.8B annualized run rate as the company plans trillion-parameter scale.
OpenAI CEO Sam Altman aims for a public listing by September 2026, with Goldman Sachs and Morgan Stanley leading underwriting efforts.
OpenAI CEO Sam Altman targets a September 2026 public offering, with Goldman Sachs and Morgan Stanley leading underwriting. Filing could happen within weeks.
Ex-OpenAI staffers and AI safety groups warn investors that xAI's safety lapses could complicate SpaceX's planned $75B IPO filing.
Preemptive investor bids have pushed Anthropic's potential valuation to $900B, fueled by a fourfold revenue surge that took its annual run rate from $9B to roughly $40B in months.